Table 3. OR (95% CI) of breast cancer in post-menopause women according to the use of hormone replacement therapy.

		Age adjusted	Multivariate Adjusted*	Multivariate Adjusted**
	Case/Control	OR (95% CI)	OR (95% CI)	OR (95% CI)
Never user	419/478	1.00 (reference)	1.00 (reference)	1.00 (reference)
Ever user	133/87	1.78 (1.32–2.41)	1.45 (1.01–2.08)	1.41((1.01–1.99)
Time since last use
Never	419/478	1.00 (reference)	1.00 (reference)	1.00 (reference)
Past	89/56	1.60 (1.10–2.32)	1.45 (0.97–2.17)	1.40 (0.93–2.13)
Recent (***)	35/17	2.19 (1.19–4.03)	1.86 (0.97–3.55)	1.82 (0.94–3.54)
P trend		0.0009	0.02	0.03
Total duration of use
Never	419/478	1.00 (reference)	1.00 (reference)	1.00 (reference)
< 5 years	96/63	1.54 (1.08–2.20)	1.48 (1.01–2.17)	1.42 (0.96–2.11)
> 5 years	29/11	2.79 (1.36–5.73)	1.95 (0.90–4.26)	1.96 (0.87–4.39)
P trend		0.006	0.07	0.10
Type of treatment
Never	419/478	1.00 (reference)	1.00 (reference)	1.00 (reference)
Estrogen alone	44/34	1.36 (0.84–2.20)	1.14 (0.68–1.91)	1.17 (0.69–2.00)
Estrogen/Progestin	22/12	2.26 (1.07–4.80)	1.85 (0.84–4.07)	1.89 (0.84–4.29)

(*) Adjusted for: age, socioeconomic status (high/medium/low), BMI (kg/m2), familial history of breast cancer in first degree relatives (yes/no), diabetes(yes/no), number of full term pregnancy, age at first full term pregnancy (years), total duration of breast feeding (months) and age at menarche (years).

(**) additional adjusted for European ancestry.

(***) We defined the recent use as the reported use of menopausal hormone therapy during the year prior to the date of interview.